Search research articles
Contact Us
Filters
Showing results (551-560 of 573) with videos related to
Page
of 58
Sort By:
British Journal of Cancer
|
April 11, 2019
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial
Karin Ribi, Weixiu Luo, Marco Colleoni, et al.
British Journal of Cancer
|
January 18, 2020
Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial
Karin Ribi, Weixiu Luo, Marco Colleoni, et al.
The Lancet. Oncology
|
November 22, 2017
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
Marco Colleoni, Weixiu Luo, Per Karlsson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 26, 2008
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial
M Untch, R D Gelber, C Jackisch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 9, 2022
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT
Prudence A Francis, Gini F Fleming, István Láng, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 13, 2021
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy
G Jerusalem, S Farah, A Courtois, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 27, 2018
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial
Thomas Ruhstaller, Anita Giobbie-Hurder, Marco Colleoni, et al.
Breast (Edinburgh, Scotland)
|
March 20, 2012
1st International consensus guidelines for advanced breast cancer (ABC 1)
F Cardoso, A Costa, L Norton, et al.
The New England Journal of Medicine
|
October 21, 2005
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
Martine J Piccart-Gebhart, Marion Procter, Brian Leyland-Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 21, 2020
Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial
Elena Guerini-Rocco, Kathryn P Gray, Caterina Fumagalli, et al.
Page
of 58
Search research articles
Search
Showing results (551-560 of 573) with videos related to
Sort By:
Page
of 58
British Journal of Cancer
|
April 11, 2019
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial
Karin Ribi, Weixiu Luo, Marco Colleoni, et al.
British Journal of Cancer
|
January 18, 2020
Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial
Karin Ribi, Weixiu Luo, Marco Colleoni, et al.
The Lancet. Oncology
|
November 22, 2017
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
Marco Colleoni, Weixiu Luo, Per Karlsson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 26, 2008
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial
M Untch, R D Gelber, C Jackisch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 9, 2022
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT
Prudence A Francis, Gini F Fleming, István Láng, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 13, 2021
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy
G Jerusalem, S Farah, A Courtois, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 27, 2018
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial
Thomas Ruhstaller, Anita Giobbie-Hurder, Marco Colleoni, et al.
Breast (Edinburgh, Scotland)
|
March 20, 2012
1st International consensus guidelines for advanced breast cancer (ABC 1)
F Cardoso, A Costa, L Norton, et al.
The New England Journal of Medicine
|
October 21, 2005
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
Martine J Piccart-Gebhart, Marion Procter, Brian Leyland-Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 21, 2020
Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial
Elena Guerini-Rocco, Kathryn P Gray, Caterina Fumagalli, et al.
Page
of 58